Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 6/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.73 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.71 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.71 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.71 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.71 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | BLM | P54132 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL2020883 | 1.00 | P2RY1 (0.73) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL18089839 | 0.95 | ADORA3 (0.73) | LMNAADORA3 | |
| SCHEMBL2461484 | 0.95 | ADORA3 (0.73) | LMNAADORA3 | |
| SCHEMBL10073439 | 0.95 | ADORA3 (0.73) | LMNAADORA3 | |
| SCHEMBL2461486 | 0.95 | ADORA3 (0.73) | LMNAADORA3 | |
| Pyrophosphoric Acid SCHEMBL3227391 | 0.94 | P2RY1 (0.79) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| Pyrophosphoric Acid SCHEMBL1321910 | 0.91 | BLM (0.76) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL2527383 | 0.87 | P2RY1 (0.86) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL3490789 | 0.87 | P2RY1 (0.86) | P2RY1ENPP1P2RY12P2RY11P2RX1 | |
| SCHEMBL8862410 | 0.87 | P2RY1 (0.86) | P2RY1ENPP1P2RY12P2RY11P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299097-B2 | Methods for treating inflammatory disorders | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100081684-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-7405051-B2 | Method of screening antiplatelet agents | ASTELLAS PHARMA INC. (JP) | 2008-07-29 | — | — | US | disclosed |
| EP-1331228-B1 | METHOD OF SCREENING ANTIPLATELET | ASTELLAS PHARMA INC (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1331228-A1 | METHOD OF SCREENING ANTIPLATELET | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-20030124626-A1 | Method of screening antiplatelet | ASTELLAS PHARMA INC. (JP) | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081684-A1 | METHODS FOR TREATING INFLAMMATORY DISORDERS | LTB4R2, LTB4R, LTC4S | P2RY1 108/4885ENPP1 542/4885P2RY12 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.